Indication for CRS and HIPEC for peritoneal metastases of pancreatic cancer
Yurttas C, Struller F, Horvath P, Königsrainer I, Königsrainer A, Beckert S (2021)
Publication Type: Book chapter / Article in edited volumes
Publication year: 2021
Publisher: Springer International Publishing
Edited Volumes: Peritoneal Tumors and Metastases: Surgical, intraperitoneal and systemic therapy
ISBN: 9783030626402
DOI: 10.1007/978-3-030-62640-2_24
Abstract
The incidence of pancreatic cancer is constantly increasing, while the prognosis remains limited even after radical resection. Especially in case of peritoneal metastasis, survival is poor. HIPEC has been proposed as either prophylactic therapy following resection with curative intention or in combination with cytoreductive surgery in case of peritoneal metastasis. So far there is no evidence that HIPEC with or without cytoreductive surgery is beneficial in the therapy of pancreatic cancer. However, there are ongoing preclinical and clinical studies investigating intra-abdominal application of chemotherapy.
Involved external institutions
Universitätsklinikum Tübingen
Germany (DE)
Landeskrankenhaus Feldkirch
Austria (AT)
Schwarzwald-Baar Klinikum
Germany (DE)
Germany (DE)
Landeskrankenhaus Feldkirch
Austria (AT)
Schwarzwald-Baar Klinikum
Germany (DE)
How to cite
APA:
Yurttas, C., Struller, F., Horvath, P., Königsrainer, I., Königsrainer, A., & Beckert, S. (2021). Indication for CRS and HIPEC for peritoneal metastases of pancreatic cancer. In Peritoneal Tumors and Metastases: Surgical, intraperitoneal and systemic therapy. Springer International Publishing.
MLA:
Yurttas, Can, et al. "Indication for CRS and HIPEC for peritoneal metastases of pancreatic cancer." Peritoneal Tumors and Metastases: Surgical, intraperitoneal and systemic therapy. Springer International Publishing, 2021.
BibTeX: Download